Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) - Total Liabilities

Latest as of September 2024: TL120.48 Million TRY ≈ $2.70 Million USD

Based on the latest financial reports, Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) has total liabilities worth TL120.48 Million TRY (≈ $2.70 Million USD) as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Total Liabilities Trend (2020–2023)

This chart illustrates how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s total liabilities have evolved over time, based on quarterly financial data. See Oncosem Onkolojik Sistemler Sanayi ve Ti (ONCSM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Competitors by Total Liabilities

The table below lists competitors of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. ranked by their total liabilities.

Company Country Total Liabilities
Mercuries Data Systems Ltd
TW:2427
Taiwan NT$3.46 Billion
Hariom Pipe Industries Limited
NSE:HARIOMPIPE
India Rs5.71 Billion
Quoc Cuong Gia Lai JSC
VN:QCG
Vietnam ₫4.00 Trillion
Cavotec SA
ST:CCC
Sweden Skr97.39 Million
Heidelberg Pharma AG
F:HPHA
Germany €43.94 Million
Yao Sheng Electronic Co Ltd
TWO:3207
Taiwan NT$1.90 Billion
RiTdisplay Corp
TW:8104
Taiwan NT$5.23 Billion

Liability Composition Analysis (2020–2023)

This chart breaks down Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oncosem Onkolojik Sistemler Sanayi ve Ti (ONCSM) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.15 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.46 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.31 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (2020–2023)

The table below shows the annual total liabilities of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. from 2020 to 2023.

Year Total Liabilities Change
2023-12-31 TL106.61 Million
≈ $2.39 Million
-15.06%
2022-12-31 TL125.50 Million
≈ $2.81 Million
+147.27%
2021-12-31 TL50.75 Million
≈ $1.14 Million
-9.55%
2020-12-31 TL56.11 Million
≈ $1.26 Million
--

About Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.

IS:ONCSM Turkey Medical Devices
Market Cap
$139.02 Million
TL6.21 Billion TRY
Market Cap Rank
#18000 Global
#247 in Turkey
Share Price
TL260.25
Change (1 day)
-0.48%
52-Week Range
TL76.85 - TL380.00
All Time High
TL380.00
About

Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits, medical devices, and test kits in Turkey. The company offers OncoCare Monolitik, an automated chemotherapy drug preparation device; OncoCare Plus, a chemotherapy drug guide; OncoWaste and M-Waste, a hazardous waste sealing system, chemotherapy drugs, cephalosporins, penicillins,… Read more